Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001189 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| SCHEMBL2001191 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| SCHEMBL14374266 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| SCHEMBL10593392 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| SCHEMBL9734685 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| SCHEMBL10593398 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| SCHEMBL4696715 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| SCHEMBL8060653 | 1.00 | TSHR (0.60) | TSHRALDH1A1BACE1FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL1997637 | 0.99 | TSHR (0.62) | TSHRALDH1A1BACE1FABP7FABP5 | |
| Hydrochloric Acid SCHEMBL5473651 | 0.99 | TSHR (0.62) | TSHRALDH1A1BACE1FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598479-A2 | A METHOD FOR PREPARING RAMIPRIL | Aarti Healthcare Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012063252-A2 | A METHOD FOR PREPARING RAMIPRIL | AARTI HEALTHCARE LIMITED (IN) | 2012-05-18 | — | — | WO | disclosed |
| US-7935831-B2 | Process for the preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | EVONIK DEGUSSA GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-7935831-B2 | Process for the preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | EVONIK DEGUSSA GMBH (DE) | 2011-05-03 | — | — | US | disclosed |
| US-20090306404-A1 | Process for the Preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | DEGUSSA GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306404-A1 | Process for the Preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | DEGUSSA GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009122433-A2 | A PROCESS FOR PREPARATION OF RAMIPRIL | IPCA LABORATORIES LIMITED (IN) | 2009-10-08 | — | — | WO | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20070232680-A1 | PREPARATION OF RAMIPRIL AND STABLE PHARMACEUTICAL COMPOSITIONS | DR. REDDY'S LABORATORIES, INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2005121084-A1 | A METHOD OF PREPARATION OF RAMIPRIL | ZENTIVA, A. S. (CZ) | 2005-12-22 | — | — | WO | disclosed |
| US-5231084-A | ACE inhibitor | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-27 | — | — | US | disclosed |
| US-4659838-A | Method of resolving bicyclic imino-α-carboxylic acid ester racemates | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232680-A1 | PREPARATION OF RAMIPRIL AND STABLE PHARMACEUTICAL COMPOSITIONS | REN, ADRA2A, CYP3A5 | TSHR 2870/4885ALDH1A1 647/4885BACE1 1670/4885 |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, ZC3HAV1, NR1H4 | TSHR 4208/4885ALDH1A1 1770/4885BACE1 1991/4885 |
| US-20090306404-A1 | Process for the Preparation of 2-azabicyclo[3.3.0]octane-3-carboxylic Acid Derivatives | AZI2, CYP11B2, CYP51A1 | TSHR 2238/4885ALDH1A1 60/4885BACE1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.